J P Stevenson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

J P Stevenson

Showing results (21-30 of 25) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 25 results.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusionJ P Stevenson, D DeMaria, J Sludden, et al.

European Journal of Cancer (Oxford, England : 1990)|December 16, 1998

Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreasJ P Stevenson, R M Scher, R Kosierowski, et al.

European Journal of Cancer (Oxford, England : 1990)|February 14, 2004

Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancerM L Veronese, J P Stevenson, W Sun, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)J P Stevenson, K S Yao, M Gallagher, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecanR S Midgley, D J Kerr, K T Flaherty, et al.

Pageof 3

Search research articles

Showing results (21-30 of 25) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 25 results.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusionJ P Stevenson, D DeMaria, J Sludden, et al.

European Journal of Cancer (Oxford, England : 1990)|December 16, 1998

Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreasJ P Stevenson, R M Scher, R Kosierowski, et al.

European Journal of Cancer (Oxford, England : 1990)|February 14, 2004

Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancerM L Veronese, J P Stevenson, W Sun, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)J P Stevenson, K S Yao, M Gallagher, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecanR S Midgley, D J Kerr, K T Flaherty, et al.

Pageof 3